UPDATE 1-Takeda: FDA won't finish diabetes drug review on time

TOKYO, Oct 10 (Reuters) - Takeda Pharmaceutical Co (4502.T: ), Japan's biggest drugmaker, said on Friday that U.S. health authorities have not been able to complete a review of a key diabetes drug candidate on schedule due to lack of resources. The drug, called alogliptin or SYR-322, is critical to Takeda's mainstay diabetes business as it is expected to be the main replacement for its best-selling Actos. Actos, which generates almost... [read full story]